72.11.Z - Research and experimental development on biotechnology
21.10.Z - Manufacture of basic pharmaceutical substances
68.10.Z - Buying and selling of own real estate
68.20.Z - Rental and operating of own or leased real estate
70.22.Z - Business and other management consultancy activities
71.20.B - Other technical testing and analysis
72.19.Z - Other research and experimental development on natural sciences and engineering
73.11.Z - Advertising agencies activities
73.20.Z - Market research and public opinion polling
74.90.Z - Other professional, scientific and technical activities not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
K PLN | K PLN | K PLN | % | |
Assets | 310,9 | 348,3 | 356,2 | 2,3 |
Gross profit (loss) | -149 | 2,8 | -9,7 | -451,8 |
Net profit (loss) | -149 | 2,5 | -9,7 | -487,6 |
Liabilities and provisions for liabilities | 54,6 | 89,4 | 107 | 19,8 |
Income tax | 0 | 0,3 | 0 | -100 |
Working assets | 259,3 | 268,4 | 276,3 | 3 |
Equity capital | 256,4 | 258,9 | 249,2 | -3,8 |
Basic operational activity income | 152,2 | 60,4 | 0 | -100 |
% | % | % | p.p. | |
Profitability of capital | -58,1 | 1 | -3,9 | -4,9 |
Equity capital to total assets | 82,5 | 74,3 | 70 | -4,3 |
Gross profit margin | -97,9 | 4,6 | 102,5 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane